rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Daniel J. O'Connor

Director

Company insider

Files Form 4 as: Director, DiaMedica Therapeutics; President and CEO, Ambrx Biopharma; Director, Seelos Therapeutics; President and CEO, Ambrx Biopharma; Chief Executive Officer, ZyVersa Therapeutics; CEO and President, Oncosec Medical; Chief Executive Officer, Advaxis; SVP, Interim Gen. Counsel, Sec, Imclone Systems.

Every Form 4 they filed

In numbers

Trades disclosed
160
Buys
6
Sells
13
Bought
$162K
Sold
$998K
Companies
8
Companies where not an officer
2
First trade
15 Feb 2007
Last trade
1 Jun 2026
Last filed
3 Jun 2026

Companies traded

Where they are an officer
Ambrx BiopharmaDirector, Officer · last 7 Mar 20240 buys · 1 sell
Ambrx BiopharmaDirector, Officer · last 5 Jul 20230 buys · 0 sells
ZyVersa TherapeuticsDirector, Officer, 10% owner · Biotechnology · last 12 Dec 20220 buys · 0 sells
Oncosec MedicalDirector, Officer · last 30 Apr 20212 buys · 7 sells
AdvaxisDirector, Officer · last 30 Jun 20173 buys · 5 sells
Imclone SystemsOfficer · last 15 Feb 20070 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
DMAC DiaMedica TherapeuticsDirector · Biotechnology · last 1 Jun 20260 buys · 0 sells
Seelos TherapeuticsDirector · last 4 Jan 20241 buy · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
1 Jun 2026filed 3 Jun 2026DMAC DiaMedica Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—40,412 at $0.00filing
1 Jun 2026filed 3 Jun 2026DMAC DiaMedica Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—40,412 at $0.00filing
20 Feb 2025filed 24 Feb 2025DMAC DiaMedica Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—64,242 at $0.00filing
7 Mar 2024filed 7 Mar 2024Ambrx Biopharmaoption or derivativeSEC FORM 4 Code D—294,643filing
7 Mar 2024filed 7 Mar 2024Ambrx Biopharmaoption or derivativeSEC FORM 4 Code D—750,000filing
7 Mar 2024filed 7 Mar 2024Ambrx Biopharmaoption or derivativeSEC FORM 4 Code D—772,857filing
7 Mar 2024filed 7 Mar 2024Ambrx Biopharmaoption or derivativeSEC FORM 4 Code D—173,785filing
7 Mar 2024filed 7 Mar 2024Ambrx BiopharmaSEC FORM 4 Code D—48,202filing
4 Jan 2024filed 8 Jan 2024Seelos Therapeuticsoption or derivativeSEC FORM 4 Code A—1,666 at $0.00filing
11 Dec 2023filed 11 Dec 2023Ambrx BiopharmaSEC FORM 4 Code A—750,000 at $0.00filing
27 Oct 2023filed 31 Oct 2023Ambrx BiopharmaSEC FORM 4 Sold$491K50,012 at $9.82filing
5 Jul 2023filed 7 Jul 2023Ambrx Biopharmaoption or derivativeSEC FORM 4 Code A—1,216,500 at $0.00filing
26 Apr 2023filed 28 Apr 2023Ambrx BiopharmaSEC FORM 4 Code A—2,750,000 at $0.00filing
5 Jan 2023filed 5 Jan 2023Seelos Therapeuticsoption or derivativeSEC FORM 4 Code A—50,000 at $0.00filing
12 Dec 2022filed 14 Dec 2022ZyVersa Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code J—1,750filing
12 Dec 2022filed 14 Dec 2022ZyVersa Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code J—1,750filing
12 Dec 2022filed 14 Dec 2022ZyVersa Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code J—177,204 at $0.00filing
12 Dec 2022filed 14 Dec 2022ZyVersa TherapeuticsBiotechnologySEC FORM 4 Code J—1,377,598 at $0.00filing
1 Jun 2022filed 2 Jun 2022Seelos TherapeuticsSEC FORM 4 Bought$9,76016,000 at $0.61filing
6 Jan 2022filed 10 Mar 2022ZyVersa Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code J—23,404 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed19

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.